孟鲁司特联合信必可治疗儿童哮喘的疗效观察 |
| |
引用本文: | 陈云龙,潘家华,倪陈,廖承琳,张旭中,刘利梅.孟鲁司特联合信必可治疗儿童哮喘的疗效观察[J].安徽医药,2009,13(12):1547-1549. |
| |
作者姓名: | 陈云龙 潘家华 倪陈 廖承琳 张旭中 刘利梅 |
| |
作者单位: | 安徽医科大学附属省立医院儿科,安徽,合肥,230001;安徽医科大学附属省立医院儿科,安徽,合肥,230001;安徽医科大学附属省立医院儿科,安徽,合肥,230001;安徽医科大学附属省立医院儿科,安徽,合肥,230001;安徽医科大学附属省立医院儿科,安徽,合肥,230001;安徽医科大学附属省立医院儿科,安徽,合肥,230001 |
| |
摘 要: | 目的观察孟鲁司特联合信必可治疗儿童哮喘的临床疗效。方法将62例轻中度哮喘患儿随机分为两组,实验组(32例):给予信必可都保(布地奈德/福莫特罗复方制剂)80/4.5μg/吸,每日两次吸入,加孟鲁司特治疗(5 mg/次,每天一次,睡前口服);对照组(30例):信必可都保80/4.5μg/吸,每日两次吸入治疗,未加孟鲁司特。共12周,观察两组患儿临床控制情况及肺功能(PEF、FEV1、FEF75、FEF50、FEF25)改变。结果(1)临床控制率:实验组临床控制率93.7%;对照组临床控制率86.7%,两组比较差异无统计学意义(P〉0.05);(2)肺功能改善情况:实验组FEV1、PEF、FEF75、FEF50、FEF25较治疗前明显改善,差异有统计学意义(P〈0.01);与对照组比较PEV1、PEF改善率差异无统计学意义(P〉0.05),小气道功能(FEF75、FEF50、FEF25)改善率差异有统计学意义(P〈0.05)。结论孟鲁司特联合信必可用于儿童哮喘的治疗,对缓解症状和改善肺功能均能收到良好效果,尤其对小气道功能改善明显。
|
关 键 词: | 哮喘 儿童 治疗 孟鲁司特 布地奈德 福莫特罗 |
Clinical effectiveness of oral montelukast combined with inhaled symbicort in the treatment of children with asthma |
| |
Institution: | CHEN Yun-long, PAN Jia-hua, NI Chen,et al (Dept of Pediatrics, The Affiliated Provincial Hospital of Anhui Medical University,Hefei 230001, China) |
| |
Abstract: | Aim To observe the curative effect of therapeutic alliance for childish asthma with montelukast sodium and symbicort. Methods 62 cases with mild-to-moderate asthma were randomly divided into two groups, and assigned into experiment group 32 cases and control group 30 cases. The cases of experiment group were treated by montelukast sodium 5 mg orally taken once every night in addition to receiving symbicort turbuhaler (budesonide/formoterol) 80/4.5 μg twice a day in an inhaler for 12 weeks ,the cases of control group receive symbicort turbuhaler (budesonide/formoterol) 80/4.5 μg twice a day in a inhaler for 12 weeks. Clinical control, pulmonary function (PEF,FEV 1 ,FEF 25,FEF 50,FEF 75) change were observed. Results As for clinical control rate, in the 12-week experiment, the clinical control rate of experiment group is 93.7%, corresponding with control group 86.7%, there is no statistical difference in clinical control rate (P 〉 0.05 ). As for pulmonary function, FEV1, PEF, FEF75, FEF50, FEF25 of experiment group are much better in pulmonary function,there is statistical differen compared with the untreated (P 〈 0. 01 ). Compared with control group the improving rates of PEV1, PEF are statistically different, while the improving rates of FEF75, FEF50, FEF25 have no statistical difference ( P 〈 0. 05 ). Conclusion The combination of Montelukast and Symbicort can be used in asthma of children,both greater in the improvement of symptom and pulmonary function, especially in the function of small airway. |
| |
Keywords: | asthma children drug therapy montelukast budesonide formoterol |
本文献已被 维普 万方数据 等数据库收录! |
|